Monitor for the appointment or shareholder nomination of a new audit committee financial expert within the next 180 days. Absent timely compliance, expect potential downgrades in liquidity and increased volatility. Consider exposure to micro-cap biotech governance risks.
Price Chart
Executive Summary
Longeveron Inc. filed an 8-K disclosing that board member and audit committee financial expert Richard Kender resigned due to his new role at Seres Therapeutics, causing the company to fall out of Nasdaq compliance. The company appointed Dr. Roger Hajjar to the audit committee but still lacks a financial expert, triggering a delisting notice with a plan to appoint or elect a qualified director within 180 days.
Key Facts
- Richard Kender resigned from the Board and Audit Committee effective March 3, 2026, due to his appointment as Executive Chairman and Interim CEO of Seres Therapeutics.
- His resignation caused Longeveron to no longer comply with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent audit committee members, one of whom must be a financial expert.
- The company appointed Dr. Roger Hajjar to the Audit Committee on March 4, 2026, restoring the three-member requirement but still lacking a financial expert.
- Longeveron has a 180-day cure period to appoint or elect a director who qualifies as both independent and an audit committee financial expert.
- Failure to regain compliance within 180 days could result in delisting from Nasdaq.
Financial Impact
High risk of delisting, which would reduce liquidity, limit institutional ownership, and increase cost of capital. No direct financial figures disclosed.
Risk Factors
- Risk of Nasdaq delisting if a financial expert is not appointed within 180 days
- Reduced investor base and liquidity if delisted
- Ongoing governance concerns due to weakened audit committee oversight
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-024839 |
| Document: 0001213900-26-024839-index-headers.html | 0001213900-26-024839 |
| Document: 0001213900-26-024839-index.html | 0001213900-26-024839 |
| Document: 0001213900-26-024839.txt | 0001213900-26-024839 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access